by 
The bispecific antibodies market provides a promising therapeutic alternative that can address key unmet needs in oncology and other disease areas. Bispecific antibodies have the ability to bind to two non-overlapping epitopes or two different antigens simultaneously, which allows them to engage multiple pathways or bring cells together for enhanced therapeutic benefits. These antibodies have advantages over traditional monoclonal antibodies in that they can act as “molecular glue” to recruit immune cells to tumor cells, as dual- targeting agents against different disease targets, or simultaneously block multiple pathways.
Global Bispecific Antibodies Market is estimated to be valued at US$ 41.08 Mn in 2024 and is expected to exhibit a CAGR of 29% over the forecast period 2023 to 2030.
Key Takeaways
Key players: Key players operating in the bispecific antibodies are Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG.
Key players operating in the bispecific antibodies market are focusing on developing next-generation formats of bispecific antibodies with enhanced safety and efficacy profiles. For instance, Amgen’s Bixkliv has shown promising results for chronic myeloid leukemia.
Growing demand: There is growing demand for bispecific antibodies for cancer treatment due to their ability to retarget T cells against tumors with high potency and tumor-cell specificity. Their dual-antigen targeting ability allows effective activation of immune system against cancers.
Global expansion: Major players are expanding their bispecific antibody pipeline and production capacities globally. Novartis plans to build additional manufacturing facilities in North Carolina to support its pipeline including T-cell engaging bispecific antibody candidates.
Market key trends
One of the major trends in the bispecific antibodies market is the development of “unswitchable” bispecific antibodies. These antibodies are engineered for high binding affinity and specificity to prevent any off-target binding. Their dual-antigen targeting results in non dissociable molecular complexes irreversibly binding immune cells to cancer cells, resulting in efficient tumor cell destruction. This reduces safety risks and improves efficacy over reversible targeting mechanisms. Companies are exploring unswitchable bispecific formats using knobs-into-holes or CrossMab CH3 domain substitutions for next-gen cancer therapies.
Porter’s Analysis
Threat of new entrants: Developing bispecific antibodies require high investments and technological expertise limiting threat from new entrants.
Bargaining power of buyers: Presence of large players and fragmented demand from end users limits buyer power.
Bargaining power of suppliers: Established supply chain and availability of raw materials from various sources restricts supplier bargaining power.
Threat of new substitutes: Limited substitute options exist due to bispecific antibodies unique dual targeting advantage.
Competitive rivalry: Intense competition owing to increasing investigational candidates and strategic collaborations.
Geographically, North America currently holds the largest share of the bispecific antibodies market due to growing cancer prevalence and increasing FDA approvals. The region is expected to witness a 29.3% CAGR during the forecast period on the back of rising healthcare spending.
Asia Pacific is poised to experience the fastest growth over the coming years. This can be attributed to expanding healthcare infrastructure, growing disposable incomes, and increasing focus of global players on generic bispecific antibody production in economies like China and India.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
